Island Pharmaceuticals Ltd
ILA
Company Profile
Business description
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its drug candidate ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases. The company carries out its research and development activities principally in the geographic regions of Australia and the United States of America.
Contact
c/- Bio101 Financial Advisory Pty Ltd
697 Burke Road, Suite 201
Camberwell
MelbourneVIC3124
AUST: +61 370367675
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,963.50 | 29.20 | 0.33% |
| CAC 40 | 7,806.13 | 28.45 | -0.36% |
| DAX 40 | 23,988.39 | 229.11 | -0.95% |
| Dow JONES (US) | 44,895.12 | 6.80 | -0.02% |
| FTSE 100 | 9,071.01 | 49.30 | -0.54% |
| HKSE | 25,562.13 | 173.78 | 0.68% |
| NASDAQ | 21,175.03 | 66.72 | 0.32% |
| Nikkei 225 | 40,998.27 | 457.96 | -1.10% |
| NZX 50 Index | 12,910.74 | 57.28 | 0.45% |
| S&P 500 | 6,394.11 | 5.47 | 0.09% |
| S&P/ASX 200 | 8,697.70 | 30.80 | 0.36% |
| SSE Composite Index | 3,597.94 | 4.28 | 0.12% |